"Independent pricing and market access consultant with 7+ years' experience advising pharmaceutical and biotech clients on pricing, value and HTA strategy across European and global markets.

I have led projects spanning pricing and market access strategy, value proposition and dossier development, evidence generation planning, HTA strategy and submission development and market access capability building. My experience spans a broad range of therapy areas, including oncology, rare diseases, neurology, cardiovascular disease, women's health, and nephrology, supporting products from early clinical development through to launch and lifecycle management.

Recent project experience includes:
- Global price & access strategy (Stroke): Conducted payer research to validate TPP scenarios and assess evidence, pricing, and access requirements for an early-stage in-patient therapy
- Value message development (LDL-C control): Evaluated and optimised an early value story in preparation for launch. Tested messaging, mapped evidence to support each message and developed the value deck
- EU pricing strategy (Frontotemporal dementia, orphan product): Executed global payer research to identify potential reimbursement outcomes and pricing thresholds, providing the evidence for a Phase III Go/No-Go investment decision

In addition to client work, I have authored more than 20 conference presentations and posters, won an ISPOR Best Research Presentation award, and presented at HTAi on European HTA and Joint Clinical Assessment developments."